NCT07909967Recruiting
Observational Analytical Validation Study of the Replior ScratchSense
Observational Analytical Validation Study of the Replior ScratchSense for Nocturnal Scratching Assessment
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
Nocturnal scratching is a frequent and meaningful symptom in dermatological conditions such as atopic dermatitis. It may reflect underlying disease activity and can substantially disrupt overall sleep and quality of life. Existing approaches to characterizing Nocturnal Scratching-such as self-reports, sleep diaries, and video monitoring-are often subjective, labor-intensive, or lack scalability for widespread use. Emerging wearable technologies offer an alternative, by enabling objective, continuous, and non- invasive signal related to scratch behavior during sleep.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 35 (estimated)
- First submitted
- 26 Oct 2026
- Start date
- 12 Oct 2026
- Primary completion date
- 10 Dec 2026
- Lead sponsor
- Replior AB
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07909967
What you commit to
- Study type: Observational
- Planned participants: 35
- From 12 Oct 2026 to the primary completion date, 10 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recent changes in anti-pruritic treatment: Initiation or dose changes of systemic medications that may suppress nocturnal itch within the past 2 weeks, including: i. Oral corticosteroids ii. Immunosuppressive agents (e.g., cyclosporine, methotrexate) iii. Biologics (e.g., dupilumab) unless on a stable dose ≥8 weeks iv. Sedating antihistamines unless stable for ≥1 week.
- Topical treatment use: initiation of topical corticosteroids, calcineurin inhibitors, or emollients within 3 days prior to study start, and no use during the study.
Other illness
- No current or expected nocturnal itch: well-controlled conditions or no recent reports of nighttime scratching.
- Confounding movement disorders or sleep conditions: diagnosed restless legs syndrome, periodic limb movement disorder, moderate/severe obstructive sleep apnea, Parkinson's disease, or other conditions that may interfere with motion analysis.
- Severe psychiatric or cognitive impairment that could impair the ability to consent or comply with the protocol
Who the study is looking for
- Male / female participant, aged 18 to 65 years inclusive. Negative pregnancy test at screening for childbearing potential women. Presence of itch-related and/or scratching-inducing conditions: documented or self-reported history of nocturnal itching and scratching, due to conditions such as:
- Atopic dermatitis
- Chronic pruritus of unknown origin
- Other pruritic dermatological or systemic conditions. Expected Nocturnal Scratch activity: participants must: Have experienced Nocturnal Scratching in the past 7 days, and
- Be considered likely to scratch during the study period, based on medical history, clinician judgment, or recent self-report
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Eurofins Optimed 1 rue des Essarts, 38610 Gières - France Coordinator of this site? Confirm its status | Grenoble | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.